Kimberly-Clark Corporation is reportedly exploring the sale of its international tissue business, an operation valued at approximately $4 billion. The Kleenex tissue maker is working with advisers to review its tissue operations outside North America, which could lead to a partial or complete sale of the business.
Deliberations regarding this potential divestiture are currently in their early stages. The strategic review indicates a move towards optimizing Kimberly-Clark's portfolio and focusing on core, higher-performing assets.
This potential transaction could significantly reshape Kimberly-Clark's global footprint and financial strategy. Any eventual sale would depend on the outcome of the ongoing review process.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.